...
首页> 外文期刊>Radiation Protection Dosimetry >ISOEFFECTIVE DOSE: A CONCEPT FOR BIOLOGICAL WEIGHTING OF ABSORBED DOSE IN PROTON AND HEAVIER-ION THERAPIES
【24h】

ISOEFFECTIVE DOSE: A CONCEPT FOR BIOLOGICAL WEIGHTING OF ABSORBED DOSE IN PROTON AND HEAVIER-ION THERAPIES

机译:等价剂量:质子和重离子治疗中吸收剂量的生物加权的概念

获取原文
获取原文并翻译 | 示例
           

摘要

When reporting radiation therapy procedures, International Commission on Radiation Units and Measurements (ICRU) recommends specifying absorbed dose at/in all clinically relevant points and/or volumes. In addition, treatment conditions should be reported as completely as possible in order to allow full understanding and interpretation of the treatment prescription. However, the clinical outcome does not only depend on absorbed dose but also on a number of other factors such as dose per fraction, overall treatment time and radiation quality radiation biology effectiveness (RBE). Therefore, weighting factors have to be applied when different types of treatments are to be compared or to be combined. This had led to the concept of 'isoeffective absorbed dose', introduced by ICRU and International Atomic Energy Agency (IAEA). The isoeffec-tive dose D_(IsoE) is the dose of a treatment carried out under reference conditions producing the same clinical effects on the target volume as those of the actual treatment. It is the product of the total absorbed dose (in gray) used and a weighting factor W_(IsoE) (dimensionless): D_(IsoE) = D× W_(IsoE). In fractionated photon-beam therapy, the dose per fraction and the overall treatment time (in days) are the two main parameters that the radiation oncologist has the freedom to adjust. The weighting factor for an alteration of the dose per fraction is commonly evaluated using the linear-quadratic (α/β) model. For therapy with protons and heavier ions, radiation quality has to be taken into account. A 'generic proton RBE' of 1.1 for clinical applications is recommended in a joint ICRU-IAEA Report [ICRU (International Commission on Radiation Units and Measurements) and IAEA (International Atomic Energy Agency). Prescribing, recording and reporting proton-beam therapy. ICRU Report 78, jointly with the IAEA, JICRU, 7(2) Oxford University Press (2007)]. For heavier ions (e.g. carbon ions), the situation is more complex as the RBE values vary markedly with particle type, energy and depth in tissue.
机译:在报告放射治疗程序时,国际放射单位和测量委员会(ICRU)建议在所有临床相关点和/或体积上/中指定吸收剂量。此外,应尽可能完整地报告治疗情况,以便对治疗处方有充分的了解和解释。但是,临床结果不仅取决于吸收剂量,还取决于许多其他因素,例如每部分剂量,总治疗时间和放射质量放射生物学有效性(RBE)。因此,当要比较或组合不同类型的治疗时,必须应用加权因子。这导致了ICRU和国际原子能机构(IAEA)提出的“等效吸收剂量”的概念。等效剂量D_(IsoE)是在参考条件下对目标体积产生与实际治疗效果相同的临床效果的治疗剂量。它是所使用的总吸收剂量(灰色)与加权因子W_(IsoE)(无量纲)的乘积:D_(IsoE)= D×W_(IsoE)。在分级光子束治疗中,每级剂量和总治疗时间(以天为单位)是放射肿瘤学家可以自由调整的两个主要参数。通常使用线性二次(α/β)模型评估每份剂量变化的加权因子。对于质子和重离子的治疗,必须考虑辐射质量。在ICRU-IAEA联合报告[ICRU(国际辐射单位和测量委员会)和IAEA(国际原子能机构)”中,建议将1.1的“通用质子RBE”用于临床。处方,记录和报告质子束治疗。 ICRU报告78,与IAEA,JICRU联合,牛津大学出版社,第7(2)版(2007年)。对于较重的离子(例如碳离子),情况更加复杂,因为RBE值随颗粒类型,能量和组织深度而显着变化。

著录项

  • 来源
    《Radiation Protection Dosimetry》 |2011年第4期|p.481-486|共6页
  • 作者单位

    Universite Catholique de Louvain, Brussels, Belgium,ICRU, Bethesda, MD, USA;

    ICRU, Bethesda, MD, USA,CERN, Geneva, Switzerland;

    Karolinska Institutet, Stockholm, Sweden,IAEA, Vienna, Austria;

    ICRU, Bethesda, MD, USA,University of Wisconsin, Madison, WI, USA;

    ICRU, Bethesda, MD, USA;

    IAEA, Vienna, Austria,Oxford University, Oxford, UK;

    ICRU, Bethesda, MD, USA,iThemba LABS, Somerset West, 7127, South Africa;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号